Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: ACAN who wrote (11970)	9/21/2005 9:32:26 AM
From: Joseph B. Schmidt	Respond to of 23958

DNDN smokin' on news... Dendreon Announces Modulation of Trp-p8 Significantly Inhibits Tumor Growth in Vivo Data on Orally Bio-Available Trp-p8 Agonists Presented at the Ion Channel Targets Conference Sep 21, 2005 9:30:00 AM WALTHAM, Mass., Sept. 21 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced new data was presented showing that modulation of the Trp-p8 tumor target with small molecules may represent a new approach to cancer therapy. In addition, the Company has identified several lead candidates for future clinical study that are orally bio-available and potent agonists of Trp-p8. The data were presented at the Ion Channel Targets Conference here today. Dr. Sateesh Natarajan, senior scientist at Dendreon presented an abstract entitled, "Agonism of the Trp-p8 Ion Channel for the Treatment of Cancer," which focused on the discovery of potent and selective Trp-p8 small molecule agonists that stimulate the flow of cations through the Trp-p8 transmembrane cation channel and induce cell death via apoptosis in a Trp-p8-specific fashion. These potent agonists were also shown to significantly inhibit the growth of Trp-p8 positive tumors in animal models at well-tolerated doses. "Modulation of Trp-p8 has the potential to become a new and highly selective approach to cancer therapy," said David Urdal, Ph.D., Dendreon's chief scientific officer. "We have made tremendous progress on the preclinical development of Trp-p8. Based on these results, we now have the potential to produce a small molecule lead drug candidate by the end of this year." About Trp-p8 Trp-p8 is normally expressed in the prostate and over-expressed in numerous cancers and may be linked to the control of cell cycle progression, cell division and cell migration. The Trp-p8 gene was discovered and patented by Dendreon. It is over-expressed in a range of cancers, including prostate, breast, lung and colon. The gene encodes a transmembrane cation channel that is a member of the transient receptor potential (TRP) ion channel family. Dendreon has a collaborative agreement with Genentech, Inc. for the preclinical research, clinical development and commercialization of products derived from its comprehensive Trp-p8 gene program. About Dendreon Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the development of innovative cancer treatments. In addition to its immunotherapies in clinical and preclinical development for a variety of cancers, Dendreon's product pipeline also includes monoclonal antibody and small molecule product candidates. Dendreon has research and development alliances with Genentech, Inc., Abgenix, Inc. and Dyax Corp. For more information about the company and its programs, visit www.dendreon.com. Except for historical information contained herein, this news release contains forward looking statements that are subject to risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements, particularly those risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such a difference include risks that the collaboration with Genentech will not be completed as contemplated, that the company will be unable to successfully develop or commercialize its products, either alone or with collaborators, the failure by Dendreon to secure and maintain relationships with collaborators or perform obligations owed to collaborators, dependence on the efforts of third parties, the company's dependence upon intellectual property rights, Dendreon's limited operating history, risks associated with the completing or failing to complete clinical trials, the risk that the safety and/or efficacy results of a clinical trial will not support an application for a biologics license, the risk the company may not satisfy regulatory requirements and the uncertainty of Dendreon's future access to capital. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations, are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. SOURCE Dendreon Corporation ---------------------------------------------- Monique M. Greer Sr. Director Corporate Communications of Dendreon Corporation +1-206-829-1500